Zepbound (Tirzepatide) FDA Approval

In a landmark decision, the U.S. Food and Drug Administration (FDA) has granted approval for Zepbound (tirzepatide) as the first-ever treatment for moderate to severe obstructive sleep apnea (OSA) in adults with obesity. This approval introduces a new approach to managing OSA, providing an alternative or complement to traditional therapies such as continuous positive airway … Read more